RCT of Iodine-containing MNPs vs Oral Iodized Oil to Prevent Iodine Deficiency in Weaning Infants
NCT ID: NCT02421653
Last Updated: 2017-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2015-12-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months
NCT02280330
Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment
NCT05901766
Study on Physiologic Requirement and Dietary Recommended Nutrient Intake (RNI) of Iodine in Children
NCT04419103
Maternal Iodine Supplementation and Effects on Thyroid Function and Child Development
NCT00791466
Study of the Effect of Iodized Oil Supplementation During Infancy
NCT01126125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Iodine is an essential micronutrient and an integral component of the thyroid hormones, needed for normal growth and development, particularly of the brain. Thyroid hormones play a critical role for development of the central nervous system from early fetal life until well after birth. Thyroid hormone insufficiency during postnatal development is associated with sensorimotor and language deficits and hypothyroidism in infancy is associated with poorer language, memory skills, fine motor, auditory processing, attention and executive processing.
In iodine deficient areas where iodized salt coverage is poor, WHO, UNICEF and the International Council for the Control of Iodine Deficiency Disorders (ICCIDD) recommend infants between 7 and 24 months be given a daily dose of 90 µg iodine (potassium iodate) or an annual dose of 200 mg iodine (iodised oil). The scientific evidence for this recommendation is weak, however, and it is uncertain under what conditions the two prevention strategies may be applied and which of the two is best when.
The objective of this study is to evaluate the efficacy and safety of the two recommended intervention strategies in iodine-deficient weaning infants. The need for high-quality controlled studies to better understand the potential contribution and synergy of alternative strategies to help achieve optimal iodine nutrition in different population groups and settings has recently been defined as a major research priority.
Following a cross-sectional, pilot study, we will conduct a randomized controlled trial to assess the efficacy of two daily doses of iodine as potassium iodate (90 µg, 100% of the WHO recommended dose, and 45 µg, 50% of the WHO recommended dose) and the annual dose of 200 mg iodine in iodised oil, via a randomized, controlled trial in weaning infants of lactating mothers living in an area affected by mild to moderate iodine deficiency in Zamboanga del Norte, Philippines, Southeast Asia.
We will compare the efficacy of each of the iodine doses against each other, and against micro-nutrients given alone, estimate the optimal level of iodine for inclusion in MNPs, and report on the safety of these interventions in weaning infants.
This study will provide important guidance to public health experts, governments and international organisations to ensure normal infant thyroid function and growth and development.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MNP90 + INERT OIL
Daily micronutrient powders (14 micronutrients) containing 90 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
MNP90
90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
INERT OIL
Non-iodised evening primrose oil capsule; oral route; once at study start
MNP45 + INERT OIL
Daily micronutrient powders (14 micronutrients) containing 45 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
MNP45
45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
INERT OIL
Non-iodised evening primrose oil capsule; oral route; once at study start
IODISED OIL + INERT MNP
Daily inert powder (maltodextrin, no micronutrients) plus one oral dose of 200 mg iodine as iodised poppy seed oil at the study start
IODISED OIL
200 mg iodine oil capsule; oral route; once at study start
INERT MNP
Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
NON-IODISED MNP + INERT OIL
Daily micronutrient powders (14 micronutrients) without iodine plus one inert oil capsule without iodine at the study start.
INERT OIL
Non-iodised evening primrose oil capsule; oral route; once at study start
NON-IODISED MNP
Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MNP90
90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
MNP45
45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
IODISED OIL
200 mg iodine oil capsule; oral route; once at study start
INERT OIL
Non-iodised evening primrose oil capsule; oral route; once at study start
INERT MNP
Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
NON-IODISED MNP
Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For pilot - aged 6 - 18 months (+2 weeks, no infant \< 6 months)
* For intervention - aged 6 - 9 months (+2 weeks, no infant \< 6 months)
* Born to a healthy singleton pregnancy
* Term (week 38 to 42) delivery
* Family residence at the study site for at least 12 months prior to the start of the study and anticipated residence for at least a further 12 months (mother and infant)
* Exclusively breastfed for at least 2 months, or if not, having received no other sources of iodine intake (in formula, supplements, or foods)
* Signed informed consent
Exclusion Criteria
* Known history of medical illnesses
* Taking chronic medications (mother and infant)
* Use of iodine containing dietary supplements during the last 6 months (mother and infant)
* Exposure to iodine containing X-ray / CT contrast agent, skin disinfectants or medications during the last 6 months (mother and infant)
* Participation in any other clinical study (mother and infant) or participated in the pilot study (infant)
NB: Severe Acute Malnutrition is defined as being below 3 standard deviations (SD) of the WHO standard for weight-for-height ratio for infants and children aged 6 to 60 months. All infants identified with SAM will be excluded from the study and referred to hospital or nutrition clinic for treatment.
6 Months
9 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UNICEF
OTHER
Global Alliance for Improved Nutrition
OTHER
Swiss Federal Institute of Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael B Zimmermann, MD
Role: PRINCIPAL_INVESTIGATOR
ETH Zuerich
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EK-2014-N-35
Identifier Type: OTHER
Identifier Source: secondary_id
EK-2014-N-35
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.